For optimal viewing of the AACI Update click here.
News from the Association of American Cancer InstitutesDecember 2015
The Association is dedicated to reducing the burden of cancer by enhancing the impact of the nation's leading academic cancer centers.
AACI Update is an e-newsletter for the cancer center directors and key contacts at AACI member institutions and individuals interested in the cancer center-related activities of AACI. AACI Update reports on the progress of AACI initiatives and other AACI endeavors that benefit the cancer community and highlights important news and events at AACI member institutions.

AACI encourages member institutions to submit cancer center highlights to AACI Update. News briefs are linked to complete stories posted on individual cancer center websites. Please e-mail materials to aaciupdate@aaci-cancer.org. AACI reserves the right to decide whether or not materials are appropriate for inclusion.

To subscribe to AACI Update, please send an e-mail to aaciupdate@aaci-cancer.org with your name, title, address, and telephone number asking to be added to the AACI's distribution list.

To unsubscribe from AACI Update, please send an e-mail to aaciupdate@aaci-cancer.org with your name, title, and unsubscribe in the subject line to be removed from AACI's distribution list.


Mailing address:
3708 Fifth Avenue
Medical Arts Building, 503
Pittsburgh, PA 15213

Headlines

Hill Day Set for May 12
AACI's annual Hill Day is set for Thursday, May 12, 2016, in Washington, DC. The event kicks off with a Congressional reception Wednesday evening. Hill Day consists of scheduled meetings with members of Congress and their staff in which participants have the opportunity to highlight the progress taking place at our nation's cancer centers and explain how sustainable federal investments in cancer research allow for advances and improvements in cancer treatment. AACI will once again partner with the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO) for this important day in Washington. more...

AACI Update Winter Break
AACI Update will not be published in January. Many thanks to all of AACI's member centers that have submitted press releases and announcements throughout the year. Submission guidelines for AACI Update are available here.

The next AACI Update is scheduled for publication on February 1, 2016. Please keep the good news coming! more...

News from the Centers
Awards & Honors
Sancar Awarded 2015 Nobel Prize for Chemistry
UNC Lineberger Comprehensive Cancer Center
Aziz Sancar, MD, PhD, a UNC Lineberger Comprehensive Cancer Center member and professor at the UNC-Chapel Hill School of Medicine, was part of a team that mapped part of the DNA repair system that protects genes against cancer. Dr. Sancar shares the 2015 Nobel Prize in Chemistry with two other biochemists - Dr. Tomas Lindahl of the U.K. and Dr. Paul Modrich of Duke University. more...
Researchers Appointed to Global Task Force to Tackle Hard-to-Treat Cancers, Disease Relapse
Barbara Ann Karmanos Cancer Institute
Ramzi Mohammad, PhD, director of Gastrointestinal Cancer Research and Asfar Azmi, PhD, assistant professor in the Department of Oncology at the Barbara Ann Karmanos Cancer Institute and Wayne State University School of Medicine are leading a team of more than 30 researchers from across the globe to develop a comprehensive review on combination strategies to tackle hard-to-treat cancers. more...
Pratt-Chapman Recognized as Young World Cancer Leader Under 40
George Washington Cancer Institute
Congratulations to Mandi Pratt-Chapman, MA, director of the George Washington University Cancer Institute, who was chosen as a Young World Cancer Leader (under 40) by the Union for International Cancer Control. Ms. Pratt-Chapman was chosen as one of eight young leaders based on her impact and successful track record in cancer control and prevention. This distinction gave Ms. Pratt-Chapman the opportunity to attend the 2015 World Cancer Leaders' Summit in Istanbul. more...
UC San Diego Cancer Researchers Named Fellows of American Association for the Advancement of Science
UC San Diego Moores Cancer Center
Six University of California, San Diego professors have been named Fellows of the American Association for the Advancement of Science (AAAS), the world's largest general scientific society. They are among 347 members selected this year by colleagues in their disciplines to be honored for "scientifically or socially distinguished efforts to advance science or its applications." more...
Grants & Gifts
MD Anderson Receives $22.2 Million in CPRIT Research Funding
University of Texas MD Anderson Cancer Center
The University of Texas MD Anderson Cancer Center was awarded more than $22 million in research grants this week from the Cancer Prevention and Research Institute of Texas (CPRIT). Thirty-six percent of funds awarded for Individual Investigator Awards went to MD Anderson faculty as well as nearly 40 percent of funds awarded for recruitment, reflecting the excellence and impact of the institution's world-class cancer researchers and star recruitment candidates. more...
CPRIT Awards $19.6 Million for Research in Various Cancers and Cancer Biology
Simmons Comprehensive Cancer Center, UT Southwestern Medical Center
The Cancer Prevention and Research Institute of Texas (CPRIT) has awarded UT Southwestern Medical Center researchers more than $19.6 million in research grants to improve preventive, diagnostic, and therapeutic services relating to cervical, breast, lung, colon, and pediatric cancers, as well as to improve scientific understanding of cancer biology. more...
Oncology Center Received $10.4 Million to Study Intersection of Evolution, Cancer Therapy
Moffitt Cancer Center
Moffitt Cancer Center has long recognized the need to integrate mathematicians into cancer research to better understand the complex dynamics that govern cancer growth and treatment. The Integrated Mathematical Oncology Department, established in 2007 and now consisting of six faculty members, integrates their skills with cancer biologists and oncologists in teams to use mathematical models to better understand cancer progression and treatment. This team driven science has led to pioneering work that has recently been acknowledged through a $10. 4 million award from the National Cancer Institute (NCI), designating Moffitt as one of the 5 Physical Science – Oncology Centers in the United States. The other four members of the NCI's Physical Sciences – Oncology Centers Program include Harvard, University of Pennsylvania, Columbia and Northwestern. more...
Lineberger Receives $10 Million Commitment to Support Cancer Research
UNC Lineberger Comprehensive Cancer Center
The University of North Carolina at Chapel Hill has announced a $10 million gift commitment to the UNC Lineberger Comprehensive Cancer Center from Ken and Cheryl Williams of Burlington, NC. The couple has designated their gift for the Ken and Cheryl Williams Fund for Venture Initiatives at UNC Lineberger, the state's only public comprehensive cancer center. more...
Leadership Transitions
Levy Named to New VICC Informatics Leadership Role
Vanderbilt-Ingram Cancer Center
Mia Levy, MD, PhD, director of Cancer Clinical Informatics at Vanderbilt-Ingram Cancer Center (VICC), has been named director of Cancer Health Information and Strategy, a new management post that will expand her leadership role. In this newly created role, Dr. Levy will conceptualize and supervise the development of new informatics tools to support the next generation of precision cancer medicine, data analytics and cancer care coordination. more...
Kantoff Named Chair of the Department of Medicine
Memorial Sloan Kettering Cancer Center
Philip W. Kantoff, MD, has been named the new Chairman of the Department of Medicine at Memorial Sloan Kettering Cancer Center. Dr. Kantoff served the Dana-Farber Cancer Institute and Harvard Medical School since 1987 in a variety of capacities. He formally assumes his new position as George J. Bosl, MD, steps down from his role after 18 years. more...
Markey Cancer Foundation Announces New President
UK Markey Cancer Center
The University of Kentucky Markey Cancer Foundation is pleased to announce the hiring of Michael Delzotti, CFRE, CSPG, as new president and chief executive officer. Mr. Delzotti will begin his new role in early December. He joins Markey from the University of Texas MD Anderson Cancer Center in Houston, where he served as senior director of philanthropic resources. more...
Kelly Takes Reins of SWOG Lung Committee
UC Davis Comprehensive Cancer Center
Karen Kelly, MD, associate director for clinical research at the UC Davis Comprehensive Cancer Center, has been named chair of the Lung Committee of SWOG, one of the nation's leading cooperative cancer research organizations. A lung cancer specialist, Dr. Kelly will oversee the design and implementation of multidisciplinary clinical trials of new lung cancer treatments, including targeted therapies, immunotherapy and cancer biomarkers involving thousands of patients nationwide. more...
Schilder Named Phase I Clinical Research Program Leader
Sidney Kimmel Cancer Center at Thomas Jefferson University
The Sidney Kimmel Cancer Center at Thomas Jefferson University is pleased to announce the appointment of Russell Schilder, MD, as the new Phase I Clinical Research Program Leader. As the new Phase I Clinical Research Program Leader, Dr. Schilder will facilitate translational efforts that bring SKCC basic science laboratory discoveries into clinical trials. more...
Mukherjee to Lead Cancer Prevention, Control Research
University of Michigan Comprehensive Cancer Center
The University of Michigan Comprehensive Cancer Center has appointed Bhramar Mukherjee, PhD, as associate director for population science research. Dr. Mukherjee is John D. Kalbfleisch Collegiate professor of biostatistics and professor of epidemiology at the U-M School of Public Health. She also serves as the associate chair for biostatistics. In her new role, Dr. Mukherjee will oversee the Cancer Center's research on cancer screening, detection and prevention, as well as research on cancer outcomes, disparities and new models of cancer care delivery. more...
Research Highlights
Study Examines Cancer-Care Outcomes among US Hospitals
Memorial Sloan Kettering Cancer Center
A study by Memorial Sloan Kettering researchers suggests that hospitals' long-term survival outcomes for cancer patients can be assessed without data on tumor stage. Patients treated at PPS-exempt hospitals - which are highly specialized in cancer care - had higher survival rates over five years compared with other hospitals, particularly community hospitals. more...
Possible New Mechanism for Aspirin's Role in Cancer Prevention
Huntsman Cancer Institute
Aspirin has been shown to decrease the risk of colorectal cancer and possibly other cancers. However, the risk of side effects, including in some cases severe gastrointestinal bleeding, makes it necessary to better understand the mechanisms by which aspirin acts at low doses before recommending it more generally as a preventative, says Cornelia Ulrich, PhD, Senior Director of Population Sciences at Huntsman Cancer Institute. Dr. Ulrich and her collaborators used a new technique, metabolite profiling, to identify a biochemical pathway previously unknown to be regulated by aspirin. more...
Nanotech-Based Sensor Measures MicroRNAs in Blood, Speeds Cancer Detection
Indiana University Melvin and Bren Simon Cancer Center
A simple, ultrasensitive microRNA sensor developed by researchers from the School of Science at Indiana University-Purdue University Indianapolis, the IU School of Medicine and the IU Melvin and Bren Simon Cancer Center holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers. Rajesh Sardar, PhD, developed the sensor. more...
Preclinical Study in Colorectal, Head/Neck Cancers Finds Advantages for FL118 Over Similar Approved Drugs
Roswell Park Cancer Institute
In the five decades since camptothecin was first isolated from the bark of a tree used in traditional Chinese medicine and identified as a powerful anticancer agent, several thousand chemicals with similar structures and functions have been investigated. And while two of these analog compounds, irinotecan and topotecan, have been approved in the U.S. as treatments for cancer, both are associated with significant shortcomings. Researchers from Roswell Park Cancer Institute, led by Fengzhi Li, PhD, have reported findings about a new synthetic form of camptothecin, known as FL118, that appears to have greater potency, longer efficacy and fewer adverse side effects than irinotecan and topotecan. more...
Melanoma's Genetic Trajectories Are Charted in New Study
UCSF Helen Diller Family Comprehensive Cancer Center
An international team of scientists led by UC San Francisco researchers has mapped out the genetic trajectories taken by melanoma as it evolves from early skin lesions, known as precursors, to malignant skin cancer, which can be lethal when it invades other tissues in the body. Significantly, the study provides new evidence that genetic and cellular characteristics of skin lesions that are neither clearly benign moles nor malignant melanoma place them in a distinctive intermediate category, the existence of which has been hotly debated among dermatologists and pathologists. Boris Bastian, MD, PhD, was senior author on the study. more...
Team Creates Potential New Approach to Early Detection of Blood Cancer
The University of Chicago Medicine Comprehensive Cancer Center
Amittha Wickrema, PhD, and colleagues have reported that reduced DOCK4 expression leads to erythroid dysplasia in myelodysplastic syndromes (MDS). They developed a new, sensitive method for precisely calculating the extent of actin skeleton disruption in blood cells using multispectral flow cytometry, which could provide a sensitive, non-invasive way to diagnose MDS. more...
Combination Drug Therapy Approved by FDA to Treat Advanced Melanoma
Jonsson Comprehensive Cancer Center, UCLA
Researcher Antoni Ribas, MD, PhD, at the UCLA Jonsson Comprehensive Cancer Center, helped develop a combination drug therapy that has been approved by the U.S. Food and Drug Administration to treat metastatic melanoma. The therapy shows great promise for extending the lives of people with an advanced form of the disease, and it does so without causing a secondary skin cancer, a side effect seen in some patients who took only one of the drugs. more...
Hospitals Urged to Establish Bereavement Programs for Deceased Patients' Families
Dana-Farber Cancer Institute
Backed by a growing body of research, investigators at Dana-Farber Cancer Institute are calling for all hospitals to establish bereavement programs for families of deceased patients. In a paper in the November issue of the Journal of Palliative Medicine, the researchers say such programs – which guide and support people through the process of mourning a loved one – can help prevent a range of physical and mental health problems that sometimes appear following the death of a family member. more...
First Precision Medicine Trial in Cancer Prevention Identifies Molecular-based Chemoprevention Strategy
UC San Diego Moores Cancer Center
A team of scientists, led by researchers at University of California, San Diego Moores Cancer Center and The University of Texas MD Anderson Cancer Center, report that a genetic biomarker called loss of heterozygosity or LOH is able to predict which patients with premalignant mouth lesions are at highest risk of developing oral cancer. The findings present a new tool that could be used to identify patients most likely to benefit from chemoprevention - and may be applicable to preventing other types of cancer. more...
Educators Show How to Bring Colorectal Cancer Information to Underserved Communities
Fox Chase Cancer Center, Temple Health
Colorectal cancer is the second-most commonly diagnosed cancer in both Hispanic men and women, a fact Fox Chase Cancer Center - Temple Health educators are working to change through dissemination of colorectal cancer information tailored to the needs of underserved Latino populations, as part of the National Cancer Institute's Center to Reduce Cancer Health Disparities, National Outreach Network. Evelyn González, MA, Senior Director of the Office of Community Outreach at Fox Chase, and her colleagues have outlined how trained community health educators can disseminate culturally appropriate, evidence-based cancer information specific to Latino communities. more...
Study Rejects Biologic Age As Limiting Factor for Stem Cell Transplants
The Ohio State University Comprehensive Cancer Center-
James Cancer Hospital & Solove Research Institute

More than 40 percent of older patients with acute myeloid leukemia (AML) can remain in long-term cancer remission through a modified, less aggressive approach to donor stem cell transplantation, according to the results of a phase 2 study led by oncologists at The Ohio State University Comprehensive Cancer Center- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. AML is an aggressive blood cancer that is life threatening and is typically diagnosed in patients older than 60. The data represents new hope in a disease where the five-year survival rate is often below 10 percent, despite achieving initial remission. more...
Changes in Brain Associated with Peripheral Nerve Issues Caused by Cancer Therapy
Indiana University Melvin and Bren Simon Cancer Center
Researchers at Indiana University School of Medicine have identified physiological changes in the brain that appear to be associated with peripheral nerve-related symptoms caused by chemotherapy. In newly reported research, scientists used magnetic resonance imaging to study changes in brain blood flow and density of gray matter in breast cancer patients receiving chemotherapy, comparing them to participants not undergoing chemotherapy. The study is believed to be the first to identify structural and functional changes in the brain associated with peripheral neuropathy caused by chemotherapy to treat breast cancer. more...
New Pancreatic Cancer Clinical Trial Uses Aggressive Treatment
University of New Mexico Comprehensive Cancer Center
A new clinical trial that recently opened at the UNM Comprehensive Cancer Center may help more people to undergo surgery to remove their pancreas tumors. And that may help more of them to live longer. The new clinical trial uses an aggressive treatment approach. The trial combines the potent chemotherapy regimen FOLFIRINOX and pinpoint-accurate stereotactic body radiation treatment with an immunotherapy drug called algenpantucel-L from NewLink Genetics. The hope is to help more borderline or non-surgical patients become candidates for surgery, says principal investigator Gregory Gan, MD, PhD. more...
Investigational Drug May Prevent Life-Threatening Muscle Loss in Advanced Cancers
The Ohio State University Comprehensive Cancer Center-
James Cancer Hospital & Solove Research Institute

New data describes how an experimental drug can stop life-threatening muscle wasting (cachexia) associated with advanced cancers and restore muscle health. The experimental agent, known as AR-42 while in testing, was developed and tested in preclinical studies at The Ohio State University Comprehensive Cancer Center- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC- James). In this new preclinical study, Tanios Bekaii-Saab, MD, and colleagues report data illustrating that orally administered AR-42 can significantly preserve body weight and prolong survival while simultaneously preventing the loss of muscle and fat tissue mass and preserving the health/strength of muscle. more...
Experimental Drug Can Help Fight Debilitating Side Effect of Ovarian Cancer
Jonsson Comprehensive Cancer Center, UCLA
Women who have ovarian cancer often develop a condition called ascites, which is a buildup of fluids in the abdomen. The most common treatment for ascites is puncturing the abdomen and manually draining the fluid, which is painful and risky and must be repeated every few weeks. UCLA researchers have found that a drug that inhibits a receptor called the Colony-Stimulating-Factor-1 Receptor, or CSF1R, reduces ascites with minimal side effects. This inhibition therapy targets not cancer cells but macrophages, a special type of immune cell, in order to prevent them from helping the cancer take root in the abdomen. more...
ONC201 Suppresses Growth Among Various Breast Cancer Cell Types
Fox Chase Cancer Center, Temple Health
A recent preclinical investigation of a novel small molecule called ONC201 suggests it could potentially offer therapeutic benefits for patients diagnosed with either triple negative or non-triple negative breast cancer. Researchers at Fox Chase Cancer Center – Temple Health presented these findings at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston in November. more...
Mathematical Modeling Can Help Predict Surgery Impact on Cancer Metastasis
Roswell Park Cancer Institute
The size of a surgically removed tumor is generally thought to relate to the risk of the cancer spreading to other regions of the body. But because tumor cells may metastasize at different times and the rate of spread is difficult to assess, the relationship between tumor size and the relative risk of recurrence after surgery is challenging to calculate. Scientists at Roswell Park Cancer Institute and Inria, the French National Institute for computer science and applied mathematics in Bordeaux, France, have demonstrated that mathematical models can provide useful clues about the impact of surgery on metastasis and may help to predict the risk of cancer spread. more...
A Cancer-Killing Cold Sore Virus Fights Late Stage Melanoma
Huntsman Cancer Institute
The U.S. Food and Drug Administration has approved, for the first time, an oncolytic viral therapy in the U.S. The drug was approved for use against late stage melanoma. The approval came as the result of a recent Phase III study, which showed that more patients with late stage melanoma, treated with a herpes cold sore virus designed to kill tumor cells, had a better response when compared to a different treatment. Robert Andtbacka, MD, from Huntsman Cancer Institute at the University of Utah and Howard L. Kaufman, MD, from Rutgers Cancer Institute of New Jersey led the multi-site study. more...
Breast Cancer in Appalachia: Surprising New Findings on Obstacles to Care
University of Virginia Cancer Center
Researchers at the University of Virginia's School of Medicine have taken a new approach to understanding why so many breast cancer patients in Appalachia aren't getting the care they need, and their findings are set to change how people view the obstacles to care that beset the region. For example, the distance patients have to travel for cancer care is often viewed as a critical factor. But UVA's findings underscore the crucial importance of access to primary-care providers who could catch cancer earlier. more...
Working Up A Sweat May Protect Men From Lethal Prostate Cancer
UCSF Helen Diller Family Comprehensive Cancer Center
A study that tracked tens of thousands of midlife and older men for more than 20 years has found that vigorous exercise and other healthy lifestyle habits may cut their chances of developing a lethal type of prostate cancer by up to 68 percent. While most prostate cancers are "clinically indolent," meaning they do not metastasize and are nonlife-threatening, a minority of patients are diagnosed with aggressive disease that invades the bone and other organs, and is ultimately fatal. Lead author Stacey Kenfield, ScD, of UCSF, and a team of researchers at UCSF and Harvard, focused on this variant of prostate cancer to determine if exercise, diet and smoke-free status might have life-saving benefits. more...
New Mode of Drug Resistance to Emerging Therapies in Prostate Cancer Identified
Fred Hutchinson Cancer Research Center
New research by scientists at Fred Hutchinson Cancer Research Center and the University of California, San Francisco sheds light on a new mode of drug resistance to emerging therapies in metastatic prostate cancer. This discovery ultimately may help predict which patients may benefit most from treatment. more...
Other News
AACR Launches International Genomic and Clinical Data-sharing Project
American Association for Cancer Research
The American Association for Cancer Research (AACR) has launched an international initiative known as AACR Project Genomics, Evidence, Neoplasia, Information, Exchange (GENIE). The initial phase of the project, which is being conducted in partnership with seven global leaders in genomic sequencing for clinical utility, as well as two informatics partners, will aggregate participants' clinical-grade sequencing data to improve patient treatment decisions and catalyze clinical and translational research. more...
Nutritional Scientist Explains Cancer-Fight Potential of Flavonoids in New Book
UK Markey Cancer Center
Plants put up a natural defense system against bacteria and disease through bioactive chemical constituents called flavonoids. In her new book, "Flavonoids, Inflammation and Cancer," Hollie Swanson, PhD, a University of Kentucky researcher in the Department of Pharmacology and Nutritional Sciences, describes how flavonoids serve a function of preventing or reducing inflammation associated with gastrointestinal and steroid-responsive cancers, including breast, bowel, colon and prostate cancers. more...
New App Launched for Breast Cancer Patients
University of Michigan Comprehensive Cancer Center
Patients being treated for breast cancer at the University of Michigan Comprehensive Cancer Center now have a new way to help manage the overload of information and reminders that comes with cancer diagnosis, surgery, chemotherapy or radiation treatment. A new first-of-its-kind mobile app called Breast Cancer Ally is available exclusively for University of Michigan patients. The free download creates a customized mobile experience based on the patient's treatment plan. Michael Sabel, MD, a breast cancer surgeon, led the app's development. more...
HJF Joins ORIEN Research Partnership
Moffitt Cancer Center
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF), in collaboration with military cancer researchers headed by the Murtha Cancer Center, is the newest member of the Oncology Research Information Exchange Network (ORIEN). Anchored by the Moffitt Cancer Center and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, ORIEN is a unique research partnership among North American cancer centers that recognizes collaboration and access to data are keys to cancer discovery. more...
Smokeless Tobacco Users Had Higher Levels of Exposure to Nicotine Than Cigarette Smokers
American Association for Cancer Research
U.S. adults who used only smokeless tobacco products had higher levels of biomarkers of exposure to nicotine and a cancer-causing toxicant—the tobacco-specific nitrosamine NNK—compared with those who used only cigarettes, according to a study published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research. more...
New Treatment for Deadliest Brain Cancer Available
University of Virginia Cancer Center
A device that represents a rare advance against glioblastoma – the deadliest form of brain cancer – is now available to newly diagnosed patients after successful testing at the UVA Cancer Center and more than 80 other sites around the world. The federal Food and Drug Administration has approved the use of the device, called Optune, in newly diagnosed patients after it was shown to extend patients' survival by approximately three months compared with standard radiation and chemotherapy treatment alone. Optune previously had been approved for use in patients with recurrent glioblastoma, or patients whose glioblastoma had progressed after radiation and chemotherapy. more...
Job Opportunities
Director  
University of Hawai'i Cancer Center

more...

Associate Director of Population Health  
Sidney Kimmel Cancer Center at Jefferson

more...

Director of Cancer Clinical Trials Operations  
UNC Lineberger Comprehensive Cancer Center

more...

Associate or Full Professor of Cancer Epidemiology  
The George Washington University (GW) Cancer Center

more...

Manager, Clinical Research  
Huntsman Cancer Institute
University of Utah

more...

Regulatory Affairs Manager  
UC Irvine, Chao Family Comprehensive Cancer Center

more...

Conflict of Interest Program Manager  
City of Hope

more...

Associate Center Director for Administration and Finance  
The George Washington University (GW) Cancer Center

more...

Meeting Announcements

Implementing Comprehensive Biopsychosocial Screening

Learn how to successfully implement biopsychosocial screening programs of excellence. Workshop is scheduled for March 1-2, 2016 in Duarte, CA. Receive up to 30 AMA PRA Category 1 Credits. Training Program is followed by APOS Meeting on March 3-5, 2016 in San Diego, CA.

For further information please email us at screeningprograms@coh.org or visit us at www.supportivecaretraining.com

Roswell Park & Lilly Diversity Workshop March 2016

Methods in Clinical Research Workshop for Minority Physicians

In an effort to increase the number of minority investigators in clinical research, the Center for Drug Development and Clinical Trials at Roswell Park Cancer Institute will conduct a training program specifically tailored to minority physicians, with support from Eli Lilly and Company. The workshop is open to under-represented minority (defined by NCI: African-American, Hispanic, Native American, and Pacific Islander) fellows and faculty in the first 5 years of their academic appointments or in private practice with a track record of significant cancer clinical trial activity.

Details of the workshop can be found here.

Click here to apply.

Spring 2016 CCAF Meeting

Save the Date!
April 3-5, 2016
Dallas, TX

Building, Implementing, and Evaluating Supportive Care Programs

Learn how to build, maintain and grow supportive care programs of excellence. Workshop is scheduled for April 21-23, 2016 in Monrovia, CA. Receive up to 21 AMA PRA Category 1 Credits.

For further information please email us at buildprograms@coh.org or visit us at www.supportivecaretraining.com

2016 Capitol Hill Day

AACI will co-host its annual Capitol Hill Day with the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO).
May 11-12, 2016
Washington, DC

8th Annual AACI Clinical Research Initiative Meeting

Save the Date!
July 20-21, 2016
Loews Chicago O'Hare Hotel

2016 AACI/CCAF Annual Meeting

Save the Date!
October 23-25, 2016
Chicago, IL